{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:16:08Z","timestamp":1770995768451,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council of Taiwan","doi-asserted-by":"crossref","award":["NSTC 113-2740-B-006-002 and NSTC 113-2311-B-006-009"],"award-info":[{"award-number":["NSTC 113-2740-B-006-002 and NSTC 113-2311-B-006-009"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Ovarian cancer is a highly prevalent cancer among women with a high risk for relapse and drug resistance. Seventy eight percent of women diagnosed with ovarian cancer live for at least one year after diagnosis. Hyptolide, a natural compound, has been shown to act as an anti-inflammatory and antibacterial agent, and latest research shows that it acts as an anticancer agent. These properties indicate that hyptolide may be a potential treatment option for ovarian cancer, including chemoresistant cases; however, its effects in chemoresistant ovarian cancer have not yet been demonstrated, and the mechanisms underlying its induction of cell death remain unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We found that hyptolide inhibited cell viability in ovarian cancer cell lines, regardless of their chemoresistance, and these effects were mediated by ER stress and the activation of GRP78 and ATF6. Combined treatment of cisplatin-resistant cell lines with hyptolide and cisplatin demonstrated a synergistic effect, enhancing apoptosis. Additionally, the reversal of chemoresistance with hyptolide treatment was mediated by \u03b2-catenin cytoplasm translocation leading to E-cadherin expression, ultimately promoting mesenchymal-epithelial transition.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our findings suggest that hyptolide induces ER stress-mediated cell death and overcomes cisplatin chemoresistance in ovarian cancer cells, supporting its potential use as a chemotherapeutic agent.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13048-025-01712-4","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T08:22:13Z","timestamp":1749716533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hyptolide induces ER stress-mediated cell death and enhances GSK3\u03b2-regulated cisplatin chemosensitivity in ovarian cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"Yusi Luluk","family":"Rahmania","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Person Pesona","family":"Renta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damar Nurwahyu","family":"Bima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Shan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngoc Thang","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiny","family":"Suzery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Tai","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"issue":"1","key":"1712_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):29\u201332. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0084.","journal-title":"Cancer Biol Med."},{"issue":"9","key":"1712_CR2","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.3390\/cancers14092230","volume":"14","author":"J Huang","year":"2022","unstructured":"Huang J, Chan WC, Ngai CH, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS. Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers. 2022;14(9):2230. https:\/\/doi.org\/10.3390\/cancers14092230.","journal-title":"Cancers"},{"issue":"2","key":"1712_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/AOG.0000000000004642","volume":"139","author":"JK Chan","year":"2022","unstructured":"Chan JK, Tian C, Kesterson JP, Monk BJ, Kapp DS, Davidson B, Robertson S, Copeland LJ, Walker JL, Wenham RM, Casablanca Y, Spirtos NM, Tewari KS, Bell JG. Symptoms of women with high-risk early-stage ovarian cancer. Obstet Gyneco. 2022;139(2):157\u201362. https:\/\/doi.org\/10.1097\/AOG.0000000000004642.","journal-title":"Obstet Gyneco"},{"issue":"3","key":"1712_CR4","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/AOG.0b013e318264f794","volume":"120","author":"LA Baldwin","year":"2012","unstructured":"Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR, Seamon LG. Ten-year relative survival for epithelial ovarian cancer. Obstet Gyneco. 2012;120(3):612\u20138. https:\/\/doi.org\/10.1097\/AOG.0b013e318264f794.","journal-title":"Obstet Gyneco"},{"issue":"4","key":"1712_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2174\/1568026620999201111155426","volume":"21","author":"B Shaik","year":"2021","unstructured":"Shaik B, Zafar T, Balasubramanian K, Gupta SP. An overview of ovarian cancer: molecular processes involved and development of target-based chemotherapeutics. Curr Top Med Chem. 2021;21(4):329\u201346. https:\/\/doi.org\/10.2174\/1568026620999201111155426.","journal-title":"Curr Top Med Chem"},{"key":"1712_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/740472","volume":"2010","author":"LJ Willmott","year":"2010","unstructured":"Willmott LJ, Fruehauf JP. Targeted therapy in ovarian cancer. J Oncol. 2010;2010: 740472. https:\/\/doi.org\/10.1155\/2010\/740472.","journal-title":"J Oncol"},{"issue":"1","key":"1712_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","volume":"81","author":"AJ Cortez","year":"2018","unstructured":"Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17\u201338. https:\/\/doi.org\/10.1007\/s00280-017-3501-8.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1712_CR8","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/gcc.20883","volume":"50","author":"J Huang","year":"2011","unstructured":"Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, Testa JR, Nathanson KL, Gimotty PA, Coukos G, Weber BL, Degenhardt Y. Frequent genetic abnormalities of the PI3K\/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosom Cancer. 2011;50(8):606\u201318. https:\/\/doi.org\/10.1002\/gcc.20883.","journal-title":"Genes Chromosom Cancer"},{"issue":"2","key":"1712_CR9","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e32","volume":"29","author":"SS Li","year":"2018","unstructured":"Li SS, Ma J, Wong AST. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism. J Gynecol Oncol. 2018;29(2): e32. https:\/\/doi.org\/10.3802\/jgo.2018.29.e32.","journal-title":"J Gynecol Oncol"},{"key":"1712_CR10","unstructured":"Lin YS, Huang WH, Hsu KF, Tang MJ, Chiu WT. Reversion of chemoresistance by endocannabinoid-induced ER stress and autophagy activation in ovarian cancer. Am J Cancer Res. 2023;13(9):4163\u221278. https:\/\/pubmed.ncbi.nlm.nih.gov\/37818056"},{"key":"1712_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113054","volume":"150","author":"S Hashem","year":"2022","unstructured":"Hashem S, Ali TA, Akhtar S, Nisar S, Sageena G, Ali S, Al-Mannai S, Therachiyil L, Mir R, Elfaki I, Mir MM, Jamal F, Masoodi T, Uddin S, Singh M, Haris M, Macha M, Bhat AA. Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agents. Biomed Pharmacother. 2022;150: 113054. https:\/\/doi.org\/10.1016\/j.biopha.2022.113054.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1712_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/14786419.2019.1628747","volume":"34","author":"FR Santana","year":"2020","unstructured":"Santana FR, Luna-Dulcey L, Antunes VU, Tormena CF, Cominetti MR, Duarte MC, da Silva JA. Evaluation of the cytotoxicity on breast cancer cell of extracts and compounds isolated from Hyptis pectinata (L.) poit. Nat Prod Res. 2020;34(1):102\u20139. https:\/\/doi.org\/10.1080\/14786419.2019.1628747.","journal-title":"Nat Prod Res."},{"issue":"14","key":"1712_CR13","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1016\/j.bmcl.2016.05.044","volume":"26","author":"G Benedekovi\u0107","year":"2016","unstructured":"Benedekovi\u0107 G, Kova\u010devi\u0107 I, Popsavin M, Francuz J, Koji\u0107 V, Bogdanovi\u0107 G, Popsavin V. New antitumour agents with \u03b1,\u03b2-unsaturated \u03b4-lactone scaffold: Synthesis and antiproliferative activity of (\u2212)-cleistenolide and analogues. Bioorg Med Chem Lett. 2016;26(14):3318\u201321. https:\/\/doi.org\/10.1016\/j.bmcl.2016.05.044.","journal-title":"Bioorg Med Chem Lett"},{"issue":"02","key":"1712_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7324\/JAPS.2020.102001","volume":"10","author":"M Suzery","year":"2020","unstructured":"Suzery M, Cahyono B, Amalina ND. Antiproliferative and apoptosis effect of hyptolide from Hyptis pectinata (L.) Poit on human breast cancer cells. J Appl Pharm Sci. 2020;10(02):1\u20136. https:\/\/doi.org\/10.7324\/JAPS.2020.102001.","journal-title":"J Appl Pharm Sci."},{"key":"1712_CR15","unstructured":"Barbosa CV, Aquino PGV, Ribeiro-J\u00fanior KAL, Moura FBP, Alexandre-Moreira MS, Sant\u2019Ana AEG, Ferreira JRO, Moraes MO, Pessoa C, Aguiar JS, Silva TG, Ara\u00fajo -J\u00fanior JX. Cytotoxic and antitumor activities of Hyptis pectinata (Sambacait\u00e1) extract. Pharmacologyonline. 2012;3:70\u22124."},{"issue":"2","key":"1712_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer. 2021;21(2):71\u201388. https:\/\/doi.org\/10.1038\/s41568-020-00312-2.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1712_CR17","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3892\/ol.2017.5580","volume":"13","author":"J Tian","year":"2017","unstructured":"Tian J, Liu R, Qu Q. Role of endoplasmic reticulum stress on cisplatin resistance in ovarian carcinoma. Oncol Lett. 2017;13(3):1437\u201343. https:\/\/doi.org\/10.3892\/ol.2017.5580.","journal-title":"Oncol Lett"},{"issue":"2","key":"1712_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.15430\/JCP.2014.19.2.75","volume":"19","author":"RK Yadav","year":"2014","unstructured":"Yadav RK, Chae SW, Kim HR, Chae HJ. Endoplasmic reticulum stress and cancer. J Cancer Prev. 2014;19(2):75\u201388. https:\/\/doi.org\/10.15430\/JCP.2014.19.2.75.","journal-title":"J Cancer Prev."},{"issue":"2","key":"1712_CR19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.canlet.2011.09.034","volume":"314","author":"Y Xu","year":"2012","unstructured":"Xu Y, Yu H, Qin H, Kang J, Yu C, Zhong J, Su J, Li H, Sun L. Inhibition of autophagy enhances cisplatin cytotoxicity through endoplasmic reticulum stress in human cervical cancer cells. Cancer Lett. 2012;314(2):232\u201343. https:\/\/doi.org\/10.1016\/j.canlet.2011.09.034.","journal-title":"Cancer Lett"},{"issue":"6","key":"1712_CR20","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.devcel.2008.05.009","volume":"14","author":"J Yang","year":"2008","unstructured":"Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818\u201329. https:\/\/doi.org\/10.1016\/j.devcel.2008.05.009.","journal-title":"Dev Cell"},{"issue":"1","key":"1712_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00018-023-05099-7","volume":"81","author":"W Xue","year":"2024","unstructured":"Xue W, Yang L, Chen C, Ashrafizadeh M, Tian Y, Sun R. Wnt\/\u03b2-catenin-driven EMT regulation in human cancers. Cell Mol Life Sci. 2024;81(1):79. https:\/\/doi.org\/10.1007\/s00018-023-05099-7.","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"1712_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.659","volume":"5","author":"X Wang","year":"2020","unstructured":"Wang X, Xue X, Pang M, Yu L, Qian J, Li X, Tian M, Lyu A, Lu C, Liu Y. Epithelial-mesenchymal plasticity in cancer: signaling pathways and therapeutic targets. MedComm. 2020;5(8): e659. https:\/\/doi.org\/10.1002\/mco2.659.","journal-title":"MedComm"},{"issue":"3","key":"1712_CR23","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/ijms22031052","volume":"22","author":"Y Kim","year":"2021","unstructured":"Kim Y, Sengupta S, Sim T. Natural and synthetic lactones possessing antitumor activities. Int J Mol Sci. 2021;22(3):1052. https:\/\/doi.org\/10.3390\/ijms22031052.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1712_CR24","doi-asserted-by":"publisher","first-page":"7267","DOI":"10.1021\/acsomega.7b00954","volume":"2","author":"M Shin","year":"2017","unstructured":"Shin M, McGowan A, DiNatale GJ, Chiramanewong T, Cai T, Connor RE. Hsp72 is an intracellular target of the \u03b1,\u03b2-unsaturated sesquiterpene lactone, parthenolide. ACS Omega. 2017;2(10):7267\u201374. https:\/\/doi.org\/10.1021\/acsomega.7b00954.","journal-title":"ACS Omega"},{"issue":"38","key":"1712_CR25","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1016\/j.tetlet.2008.07.033","volume":"49","author":"T Chakraborty","year":"2008","unstructured":"Chakraborty T, Purkait S. Total synthesis of hyptolide. Tetrahedron Lett. 2008;49(38):5502\u20134. https:\/\/doi.org\/10.1016\/j.tetlet.2008.07.033.","journal-title":"Tetrahedron Lett"},{"issue":"1","key":"1712_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12935-022-02721-9","volume":"22","author":"P Dhyani","year":"2022","unstructured":"Dhyani P, Sati P, Sharma E, Attri DC, Bahukhandi A, Tynybekov B, Szopa A, Sharifi-Rad J, Calina D, Suleria HAR, Cho WC. Sesquiterpenoid lactones as potential anti-cancer agents: an update on molecular mechanisms and recent studies. Cancer Cell Int. 2022;22(1):305. https:\/\/doi.org\/10.1186\/s12935-022-02721-9.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"1712_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.lungcan.2009.07.017","volume":"68","author":"JY Hung","year":"2010","unstructured":"Hung JY, Hsu YL, Ni WC, Tsai YM, Yang CJ, Kuo PL, Huang MS. Oxidative and endoplasmic reticulum stress signaling are involved in dehydrocostuslactone-mediated apoptosis in human non-small cell lung cancer cells. Lung Cancer. 2010;68(3):355\u201365. https:\/\/doi.org\/10.1016\/j.lungcan.2009.07.017.","journal-title":"Lung Cancer"},{"issue":"4","key":"1712_CR28","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/ijms18040792","volume":"18","author":"E Guzel","year":"2017","unstructured":"Guzel E, Arlier S, Guzeloglu-Kayisli O, Tabak MS, Ekiz T, Semerci N, Larsen K, Schatz F, Lockwood CJ, Kayisli UA. Endoplasmic reticulum stress and homeostasis in reproductive physiology and pathology. Int J Mol Sci. 2017;18(4):792. https:\/\/doi.org\/10.3390\/ijms18040792.","journal-title":"Int J Mol Sci"},{"key":"1712_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104036","volume":"101","author":"SS Wang","year":"2020","unstructured":"Wang SS, Zhang QL, Chu P, Kong LQ, Li GZ, Li YQ, Yang L, Zhao WJ, Guo XH, Tang ZY. Synthesis and antitumor activity of \u03b1,\u03b2-unsaturated carbonyl moiety- containing oleanolic acid derivatives targeting PI3K\/AKT\/mTOR signaling pathway. Bioorg Chem. 2020;101: 104036. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104036.","journal-title":"Bioorg Chem"},{"issue":"1","key":"1712_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, Zhou Z, Shu G, Yin G. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3. https:\/\/doi.org\/10.1038\/s41392-021-00762-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"1712_CR31","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.18632\/oncotarget.2957","volume":"6","author":"WT Chiu","year":"2015","unstructured":"Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC, Hsu KF, Chou CY. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget. 2015;6(4):2349\u201365. https:\/\/doi.org\/10.18632\/oncotarget.2957.","journal-title":"Oncotarget."},{"key":"1712_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.omto.2019.04.005","volume":"14","author":"Y Song","year":"2019","unstructured":"Song Y, Ye M, Zhou J, Wang ZW, Zhu X. Restoring E-cadherin expression by natural compounds for anticancer therapies in genital and urinary cancers. Mol Ther Oncolytics. 2019;14:130\u20138. https:\/\/doi.org\/10.1016\/j.omto.2019.04.005.","journal-title":"Mol Ther Oncolytics"},{"issue":"24","key":"1712_CR33","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1038\/onc.2013.279","volume":"33","author":"SH Kao","year":"2014","unstructured":"Kao SH, Wang WL, Chen CY, Chang YL, Wu YY, Wang YT, Wang SP, Nesvizhskii AI, Chen YJ, Hong TM, Yang PC. GSK3\u03b2 controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene. 2014;33(24):3172\u201382. https:\/\/doi.org\/10.1038\/onc.2013.279.","journal-title":"Oncogene"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01712-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01712-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01712-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T08:22:15Z","timestamp":1749716535000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01712-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1712"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01712-4","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}